Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, Zymeworks Extend Bi-specific Antibody Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck, Zymeworks Extend Bi-specific Antibody Alliance

Merck gains expanded access to Azymetric platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Zymeworks has extended its research collaboration with Merck, dating back to August 2011. Additionally, Merck gains expanded access to Zymeworks’ Azymetric platform for the development of novel bi-specific antibody therapeutic candidates.
 
Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies generated through use of the Azymetric platform for certain therapeutic targets. Both companies will progress bi-specific therapeutic antibody candidates in preclinical development with Merck responsible for clinical development and commercialization.
 
The Azymetric platform can be used to rapidly screen target and sequence combinations for bi-specific activities in the final therapeutic format, shortening drug development timelines.
 
“We are extremely pleased with how the strategic collaboration is progressing with Merck and we are looking forward to working even closer together with the Merck biologics team in bringing groundbreaking therapies to the clinic,” said Ali Tehrani, Ph.D., president and chief executive officer of Zymeworks.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics